Growth hormone deficiency (GHD) by and large involves a wide range of disorders, including an impairment in GH secretion and/or a reduced impact of GH (table 1) [1]. It has been proposed that GH and IGF-1 are analogous to other endocrine systems in that they are interconnected, with GH being the regulatory hormone and IGF-1 the hormone acting primarily. A distinction is thus made between 'primary IGF deficiency' , which involves IGF-1 impairment but normal GH secretion and action, whereas 'secondary IGF deficiency' is a state in which IGF-1 is impaired due to irregularities in GH secretion [2]. These disorders are diagnosed via a combination of diagnostic tools [see also chapters by Blum and Albertsson-Wikland, this vol.]. In addition, imaging techniques and molecular genetic methods [see chapter by Pandey and Mullis, this vol.] can be applied to confirm and/or specify the diagnosis.
The problem faced by the clinician in diagnosing GHD has been examined from different levels [3] [4] [5] [6] [7] [8] .
1 The first difficulty is in defining the diagnostic entrance criteria in such a way that the secondary diagnostic steps can thereby be justified and not excluded. If very stringent criteria (e.g. cut-offs) are a constituent part of the initial diagnostic steps, some individuals may possibly be excluded from the further work-up. This is an error of the first order (although the patient is affected, she/he is defined as healthy). On the other hand, the criteria must be chosen in such a way as to avoid an error of the second order (the individual is considered sick, and therefore subjected to further -possibly unnecessary -diagnostic procedures; however, she/he is in fact healthy). 2 In a second step, proof of an impairment in GH secretion must be obtained. The strain on the patient, arising from the scope of the diagnostic procedure, should be limited and errors of the first or second order should be minimized. 3 In a third step, techniques to define the causes of impaired GH secretion need to be applied. 4 Finally, there is the question about whether the altered signs and symptoms resulting from the normalization of GH through replacement therapy can be used to confirm or refute the diagnosis of GH impairment, and thus become part of a 'secondary' diagnostic step [9, 10] . 
Considerations before GH Testing

Entrance Criteria
It is important to ensure that a combination of various anamnestic, auxological and biochemical information is available before GH testing is done in infants, children and adolescents with GHD, as this is crucial to establishing the diagnosis of GHD firmly (table 2). The proper classification of a disorder on the GH-IGF axis must be based on biochemical analyses (table 3). History Genetic forms of isolated or combined GHD are rare and only occur in about 3% of cases [11, 12] . Thus, in addition to measuring height in both parents, a detailed family history needs to be recorded. Other historical events, such as head trauma [13] or treatment for malignancies [14, 15] are also strong indicators of GHD in a short child.
Perinatal History and Signs
In the early years of research on GHD, it was observed that a high proportion of affected children were delivered vaginally and in a breech position [16] . Whether GHD is caused by a trauma possibly occurring during such a delivery has yet to be clarified. Evidence has also to be found for pituitary defects in the fetus which possibly led to a breech position. It is standard practice to perform a caesarean section in most cases in which an unfavorable presentation at birth is apparent. Nevertheless, a head trauma during delivery may cause pituitary damage similar to postnatal head trauma [13] . A small penis and bilateral undescended testes can be an indication of insufficient fetal exposure to gonadotrophins/testosterone in males. This may be associated with GHD. Prolonged jaundice may also be a symptom of GHD combined with hypocortisolism [17] . Hypoglycemia may occur in congenital GHD [18] ; however, it is not clear whether this is possibly the result of isolated GHD or, instead, of GHD combined with other pituitary defects. In these instances GHD can be suspected even if small body size (length) is not a presenting symptom.
Phenotypic Appearance Children with severe GHD have a relatively large neurocranium in relation to the mid-facial region. This gives them a typical 'doll-like' appearance. Head circumference is about 2 SDS above height SDS [19] ; thus, microcephaly is a very unlikely feature of GHD. Typical characteristics include small hands and feet and a less mature 
voice, and the overall appearance does not correspond with age. Frequently, however, the appearance of children with GH is not conspicuous.
Anthropometric Symptoms at Presentation
The most frequent sign of GHD in a child is height development [20, 21] . Short stature is defined as height/length below the 3rd centile for age. Children with GHD are less likely to present with a height of >-2.5 SDS [22] . In addition, the child's height/ length needs to be examined in relation to parental height [23] . It is uncommon for a child's height to be within the range of the reference population but outside the target range for the parents (roughly: height SDS minus MPH SDS <-1.3 SDS), and further diagnostics are required to identify GHD. Since shortness in children with GHD is proportional (sitting height and arm span deviate to the same degree as does height), these anthropometrical parameters need to be documented and compared with appropriate references. Another important aspect to consider is height within the context of delayed puberty [24] , as this is an explicit indicator of GHD. The height of children with pubertal age but prepubertal stage may be compared with extrapolated references based on the ICP model devised previously [25] [26] [27] .
Since growth is not static, like height, but takes place in a dynamic process, height velocity is considered the more appropriate parameter for defining abnormal growth. Duche et al.
[8] observed a sensitivity of 92%, with a specificity of 72%, in diagnosing GHD by combining a height velocity of <-1.0 SDS with an IGF-1 SDS of <-2.0 SDS. However, the difficulty in applying height velocity is that two measurements must be taken at appropriate intervals in order to obtain an exact calculation. The time frame for the two measurements must include a stage of height velocity (the lower, the longer) and the calculation depends on the precision of the measuring device. Usually, data relating to 6 (infancy) to 12 (childhood) consecutive months are needed to establish accurate height velocity. If the diagnosis of GHD is likely in a given child, the diagnostic (therapeutic) process should not be delayed for the sake of height velocity, whereas a delay would be justified if the diagnosis of GHD is less likely. The question about which limits should be considered as abnormal in a short child is still controversial. A child with normal size at birth, who however grows slowly, will obviously have short stature. It is not clear what height velocity can be expected once height is below the normal range. If growth dynamics are expressed in terms of delta height (SDS), then a value below -0.5 SDS is congruent with normal variation. If growth dynamics are expressed in terms of height velocity (cm/year), then a value above the 25th centile for age (equal to approximately -1.0 SDS) is not very likely in a child with GHD, and a value above the 50th centile for age (approximately -0.0 SDS) is highly unlikely in GHD. In children at pubertal age but delayed puberty, special references need to be considered [28] .
It is a common assumption that bone age (BA) is delayed and BA progression is retarded in GHD. However, there is considerable overlap in normal or short non-GHD children [29] . This may be due to the following reasons: (1) bone age determinations are prone to subjective error, (2) appropriate, contemporary references are usually not available, (3) there is a natural variation in BA at a given chronological age, and (4) bone age is not completely independent of height, with smaller children in an age cohort presenting with lower BA. Nevertheless, a bone age equivalent to or higher than chronological age is not likely in GHD.
In GHD, weight is typically not diminished to the same degree as is height [30] (weight SDS minus height SDS > +1.0 SDS). The children look relatively wellnourished. However, overt obesity is the exception in congenital GHD. Although the deficit in muscle mass and the relative abundance of subcutaneous fat can be documented in GHD by means of special techniques [31] , body composition assessment is at present not considered to be a standard component in the diagnostics of short stature. The same is true for bone mass determinations [32] . Since these aspects are significant in treating patients with permanent GHD during the transition to adult age, it is probable that pediatric practices relating to diagnosis and follow-up will be adapted for adult care in future.
Biochemical Markers of GHD It is a well-known fact that various circulating biochemical compounds depend on GH secretion. Indicators of bone growth (e.g. alkaline phosphatase) and collagen metabolism are low in GHD patients, but normalize during GH therapy [see also article by Crofton, this vol.]. Particular mention must be made of the GH-dependent factors in the IGF system (e.g. IGF-1, IGFBP-3) whose role in the diagnostics of GHD in children and adults has been a controversial matter for the past few decades. The main issues pertain to the partial effects of both GH and IGF-1 at the sites of growth as well as to the relevance of circulating IGF-1 during growth [33] [34] [35] . A more specific discussion focused on the diagnostic role of IGF-1 (and IGFBP-3) blood levels in GHD. IGF measurements are advantageous because they can easily be obtained from a single sample; in addition, reference levels for children and adolescents are available [see chapter by Blum]. It must be remembered that this debate on the diagnostic role of IGFs is related to the fact that a 'golden standard' for establishing the diagnosis of GHD does not exist. Authors have associated the diagnosis of GHD with the degree of sensitivity and specificity of IGF-1 (IGFBP-3) by means of their own definitions and diagnostic settings [36] . Interim conclusions show that low levels (in relation to age and sex) of IGF-1 (IGFBP-3) support the diagnosis of GHD, whereas normal levels (e.g. IGF-1 > -1.0 SDS; IGFBP-3 > 0.0 SDS) do not [37, 38] (table 2) . Thus, IGF measurements have become an essential part of the work-up for GHD.
Pituitary Imaging Special cerebral imaging techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI) were conventionally done after the diagnosis of GHD was established, with the aim of ascertaining the cause of GHD. A high frequency of abnormalities in the hypothalamus-pituitary region was documented by means of MRI in children with GHD [39] . A strong but not definite indicator of GHD could be an impairment in the size of the anterior pituitary, if MRI shows no evidence of a structural abnormality in the pituitary region [40] . The ready accessibility of imaging tools has led to a growing demand for techniques providing immediate results; however, although these methods are non-invasive, they are not necessarily suitable for examining younger children. In addition, operating the equipment and interpreting the results require considerable skill. A simple X-ray may often be more helpful in the further diagnostics of short stature in a child; e.g. calcifications in the pituitary region have explained 90% of craniopharyngioma cases.
Growth Hormone
Natural Variation of GH Molecules
GH is the gene product of the GH-N gene which is primarily expressed in the somatotrophs of the pituitary but also, to a lesser degree, in other tissues [41, 42] . The major gene product (approximately 80-90%) is a peptide hormone of 191 amino acids (size 22 kDa); however, due to alternative splicing, a shorter form (lacking amino acids 32-46; size 20 kDa) is also produced, which accounts for 10-20%. Shorter and larger forms are also formed in the circulation, either by means of proteolytic fragmentation or as a result of an association of forms of GH. Thus, there is not only one natural GH, and the circulating amount of the different components may depend on their production, metabolic circumstances and varying degrees of degradation [43] . In the human placenta, a GH-variant gene (GH-V) is expressed. Since three different variants of the GH receptor exist, which, through conformational changes during GH binding, transmit signals to the target cell [44] , it is conceivable that the different forms of circulating GH exert different effects [45] . GH forms also vary, depending on GHsecretory stimuli [46] .
GH-Binding Protein
There is an additional level of complexity arising from the fact that the external part of the GH receptor can be cleaved into the circulation by proteolysis and can bind GH [47] . It is assumed that up to 50% of circulating GH is complexed to this GH-binding protein (GHBP) [48, 49] . GHBP prolongs the half-life of GH by protecting it from degradation. The GH-GHBP complex is a hormone reservoir. Several reports refer to immunometrical assays used to determine GHBP [50] [51] [52] [53] . The assays have not been standardized, and there is no international reference preparation available for GHBP. However, measurements in normal adults show that serum GHBP are relatively constant (ranging between approximately 0.5 to 3.8 nmol/l) and correlate positively with BMI and negatively with age. GHBP levels are low during fetal life, rise in the first years after birth and thereaf
